Tickborne Rickettsial Disease (TBRD) Investigation Guideline
[Including Anaplasmosis, Ehrlichiosis, and Spotted Fever Rickettsiosis]

Contents
CASE DEFINITION ................................................................................................................................. 1
LABORATORY ANALYSIS ....................................................................................................................... 3
EPIDEMIOLOGY ....................................................................................................................................... 4
DISEASE OVERVIEW .............................................................................................................................. 5
NOTIFICATION TO PUBLIC HEALTH AUTHORITIES .............................................................................. 6
INVESTIGATOR RESPONSIBILITIES ..................................................................................................... 6
STANDARD CASE INVESTIGATION AND CONTROL METHODS .......................................................... 7
  Case Investigation ................................................................................................................................ 7
  Contact Investigation .......................................................................................................................... 8
  Isolation, Work and Daycare Restrictions ........................................................................................... 8
  Case Management ............................................................................................................................. 8
  Contact Management ........................................................................................................................ 8
  Environmental Measures .................................................................................................................... 8
  Education ............................................................................................................................................. 9
DATA MANAGEMENT AND REPORTING TO THE KDHE .................................................................... 10
ADDITIONAL INFORMATION / REFERENCES ...................................................................................... 11
  Testing for evidence of Heartland and Bourbon Virus disease (July 2018) ............................................. 12
  Ehrlichiosis/Anaplasmosis Fact Sheet
  Spotted Fever Rickettsiosis Fact Sheet

Attachments can be accessed through the Adobe Reader’s navigation panel for attachments. Throughout this document attachment links are indicated by this symbol ; when the link is activated in Adobe Reader it will open the attachments navigation panel. The link may not work when using PDF readers other than Adobe.
## Revision History:

<table>
<thead>
<tr>
<th>Date</th>
<th>Replaced</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/2020</td>
<td>05/2018</td>
<td>Updated case definition in association to Spotted Fever Group (SFGR). Minor edits to lab analysis (SFGR and PCR) and Epidemiology and Disease Overview (Rickettsialpox). Edits to case investigation in relation to situations not requiring further investigation. Removed reference to K-State Insect Diagnostician. Removed EpiTrax tab references and minor formatting throughout. Added 2018 on testing for Heartland and Bourbon Virus.</td>
</tr>
<tr>
<td>05/2018</td>
<td>01/2016</td>
<td>Updated Notification Section with requirements of new reporting regulations.</td>
</tr>
<tr>
<td>01/2016</td>
<td>09/2011</td>
<td>Combined the Anaplasmosis/Ehrlichiosis and Spotted Fever Rickettsiosis guidelines into one Tickborne Rickettsial Disease Investigation guideline. Updated Notification, Investigator Responsibilities, and Data Management sections with disease surveillance indicator targets.</td>
</tr>
<tr>
<td>12/2013</td>
<td>04/2009</td>
<td>Reformatted and added notification section.</td>
</tr>
</tbody>
</table>
CASE DEFINITION

Clinical Description for Public Health Surveillance:
- Anaplasmosis and Ehrlichiosis – Any reported fever AND one or more of the following: headache, myalgia, anemia, leukopenia, thrombocytopenia, or any hepatic transaminase elevation.
- Spotted Fever Rickettsiosis – Fever as reported by the patient or a healthcare provider, AND one or more of the following: rash, eschar, headache, myalgia, anemia, thrombocytopenia, or any hepatic transaminase elevation.

Laboratory Criteria for Case Classification:

**Laboratory confirmed:**
- Anaplasmosis and Ehrlichiosis:
  - Detection of DNA in a clinical specimen via amplification of a specific target by PCR assay, OR
  - Serological evidence of a fourfold change in immunoglobulin G (IgG)-specific antibody titer between paired serum specimens (one taken in the first week of illness and a second 2-4 weeks later), OR
  - Demonstration of antigen in a biopsy or autopsy specimen by IHC, or
  - Isolation from a clinical specimen in cell culture.
- Spotted Fever Rickettsiosis (SFGR):
  - Detection of SFGR nucleic acid in a clinical specimen via amplification of a *Rickettsia* genus- or species-specific target by PCR assay, OR
  - Serological evidence of a fourfold increase in IgG-specific antibody titer reactive with SFGR antigen by indirect immunofluorescence antibody assays (IFA) between paired serum specimens (one taken in the first two weeks after illness onset and a second taken two to ten weeks after acute specimen collection) *, OR
  - Demonstration of SFGR antigen in a biopsy or autopsy specimen by immunohistochemical methods (IHC), OR
  - Isolation of SFGR from a clinical specimen in cell culture and molecular confirmation (e.g., PCR or sequence).

**Laboratory presumptive** for Spotted Fever Rickettsiosis (SFGR):
- Serologic evidence of elevated IgG antibody at a titer $\geq 1:128$ reactive with SFGR antigen by IFA in a sample taken within 60 days of illness onset.

**Laboratory supportive:**
- Anaplasmosis and Ehrlichiosis:
  - Serologic evidence of elevated IgG ($>1:64$) or immunoglobulin M (IgM) antibody.
  - Identification of morulae in cytoplasm of neutrophils or eosinophils (for *Anaplasma phagocytophilum*), or of monocytes and macrophages (for *Ehrlichia chaffeensis*) by microscopic examination.
- Spotted Fever Rickettsiosis (SFGR):
  - Serologic evidence of elevated IgG antibody at a titer $<1:128$ reactive with SFGR antigen by IFA in a sample taken within 60 days of illness onset.

*A four-fold rise in titer should not be excluded (as confirmatory laboratory criteria) if the acute and convalescent specimens are collected within two weeks of one another.*
Exposure:
Exposure is defined as having been in potential tick habitats within the past 14 days before onset of symptoms. Occupation should be recorded if relevant to exposure. A history of a tick bite is not required.

Case Classification:
- **Confirmed:** A clinically compatible case (meets clinical evidence criteria) that is laboratory confirmed.

- **Probable:**
  - Anaplasmosis and Ehrlichiosis:
    - A clinically compatible case (meets clinical evidence criteria) that has supportive laboratory results.
      (An “Ehrlichiosis/Anaplasmosis, undetermined” case can only be classified as probable. This occurs when a case has compatible clinical criteria with laboratory evidence to support Ehrlichia/Anaplasma infection, but not with sufficient clarity to definitively place it in one of the categories previously described. This may include the identification of morulae in white cells by microscopic examination in the absence of other supportive laboratory results.)
  - Spotted Fever Rickettsiosis (SFGR):
    - A clinically compatible case (meets clinical criteria) that has presumptive laboratory evidence.

- **Suspect:**
  - A case with confirmatory or presumptive laboratory evidence of infection with no clinical information available, **OR**
  - A clinically compatible case (meets clinical criteria) that has supportive laboratory evidence.
LABORATORY ANALYSIS:

- Clinical suspicion of any of these diseases is sufficient to begin treatment. Delay in treatment may result in severe illness and death.
- The State Public Health Laboratory does not provide testing and sends all specimens to the CDC. **Warning:** Prior consultation required from the KDHE Epidemiology Program at 1-877-427-7317. CDC does not offer routine testing – illness MUST meet clinical case definition.

<table>
<thead>
<tr>
<th>Laboratory Findings</th>
<th>Anaplasmosis</th>
<th>Ehrlichiosis</th>
<th>Spotted Fever</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anemia</td>
<td>Mild</td>
<td>May occur late in illness</td>
<td>--</td>
</tr>
<tr>
<td>Thrombocytopenia</td>
<td>Yes</td>
<td>--</td>
<td>Yes</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>Relative and absolute; lymphopenia and left shift</td>
<td>Absolute</td>
<td>--</td>
</tr>
<tr>
<td>Blood smear: morulae in cytoplasm</td>
<td>In granulocytes</td>
<td><em>E. chaffeensis:</em> in monocytes <em>E. ewingii:</em> in granulocytes</td>
<td>--</td>
</tr>
<tr>
<td>Elevated Transaminase</td>
<td>Mild to moderate in some patients</td>
<td>Mildly elevated</td>
<td></td>
</tr>
<tr>
<td>Hyponatremia</td>
<td>--</td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>Skin biopsy: DNA detection by PCR; or IHC staining of organism</td>
<td>--</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Whole blood sample: DNA detection by PCR</td>
<td>Most sensitive in first week of illness; sensitivity may decrease after administration of antibiotics</td>
<td>Negative in first days of illness. More reliable during severe phase or for autopsy specimens.</td>
<td></td>
</tr>
<tr>
<td>Serology</td>
<td>Antibodies are detectable 7–10 days after illness onset. The gold-standard serologic test looks for a four-fold change in IgG-specific antibody titers using immunofluorescence assay (IFA) on paired samples. The first sample should be taken within the first or second week of illness and the second should be taken 2 to 4 weeks later.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** IgM antibodies are less specific than IgG antibodies and are more likely to generate false positives. Do not use IgM results alone for laboratory diagnosis.

**NOTE:** Antibody titers are frequently negative in the first 7–10 days of illness, thus serologic tests may be falsely negative during this period.
EPIDEMIOLOGY
The tickborne rickettsial disease (TBRD), including Rocky Mountain Spotted Fever (RMSF), Ehrlichioses (HME), and Anaplasmosis (HGA) are caused by *Rickettsia rickettsii*, *Ehrlichia chaffeensis*, and *Anaplasma phagocytophilum*, respectively. These pathogens are maintained in nature by interactions of wild mammals with hard-bodied (ixodid) ticks. The epidemiology of these diseases reflects the geographic distribution and seasonal activities of the vectors and reservoirs and the human behaviors that place persons at risk for tick attachment and subsequent infection. RMSF, HME, and HGA are reported each month of the year in the United States, although 90%-93% of reported cases occur during April-September during peak levels of tick feeding activity on humans. Travelers outside of the United States might also be exposed to other tick vectors in other countries that transmit related agents that result in disease after they return to the United States.

Males appear to be at higher risk for infection with all TBRD, possibly because of recreational or occupational exposures to tick habitats. Although previous studies have indicated that the highest incidences of RMSF have occurred in children aged <10 years, surveillance during 2003 demonstrates a higher age-specific incidence for RMSF among persons aged 40-64 years, compared with other age groups. For HME and HGA, the highest age-specific incidences occurred among persons aged >70 and 60-69 years, respectively. The higher frequency of disease reporting in adults might reflect greater susceptibility to recognizable disease rather than higher infection rates. Deaths from TBRD are rare, but severe complications can occur. Even in the absence of the most severe complications, hospitalizations due to these diseases are common. From 2012 through 2014, 54 to 61 percent of Kansas ehrlichiosis/anaplasmosis cases were hospitalized, and 22 to 30 percent of RMSF cases were hospitalized. (Source: MMWR, 2006)

RMSF is reported as “spotted fever rickettsiosis” (SFGR) to allow reporting of all spotted fever cases to the CDC, including those caused by *R. parkeri* and *R. 364D*. Spotted fever cases are found throughout the contiguous U.S., but five states (North Carolina, Oklahoma, Arkansas, Tennessee, and Missouri) account for over 60% of RMSF cases. In eastern Arizona, RMSF cases associated with exposure to the brown dog tick (*Rhipicephalus sanguineus*) have recently been identified in an area where RMSF had not previously been seen. Rickettsialpox is caused by *R. akari* is spread through the bite of infected house mouse mites (*Liponyssoides sanguineus*) with cases occurring sporadically throughout the United States, but are often reported in the Northeast, particularly New York City.

Anaplasmosis is most frequently reported from the upper midwest and northeastern U.S. Ehrlichiosis is most frequently reported from the southeastern and south-central U.S., from the eastern seaboard extending westward to Texas. In 2009, a new *Ehrlichia* species, provisionally called *Ehrlichia* muris-like (EML) was identified among patients in the upper Midwest.
DISEASE OVERVIEW

A. Agent:
   - *Ehrlichia chafeensis* and *E. ewingi*, gram-negative bacteria associated to human monocytic ehrlichiosis (HME). Other species, including *Ehrlichia muris-like* (EML), are also associated to human illness.
   - *Anaplasma phagocytophilum*, gram-negative bacteria associated to human granulocytic anaplasmosis (HGA) which was previously referred to as human granulocytic ehrlichiosis (HGE).

B. Clinical Description:
   A tick-borne illness is characterized by acute onset of fever and may be accompanied by headache, myalgia, malaise, anemia, thrombocytopenia, or elevated hepatic transaminases. Nausea, vomiting, or rash may be present.
   - Infections caused by *R. parkeri*, *R. species* 364D, or *R. akari* are less severe than *R. rickettsii* (RMSF). A spotted fever group illness may have an ulcerated, necrotic region at the site of tick or mite attachment, called eschars. Ricettsialpox developing from *R. akari* infections are characterized by papulovesicular eruptions, while the other spotted fever rashes when present are macular or maculopapular rashes. The rash may be absent in 20% of patients and some people do not develop the rash until late in the disease process after treatment has begun.
   - Those with anaplasmosis or ehrlichiosis may exhibit leukopenia and morulae may be observed in monocytes or granulocytes on blood smears.

C. Reservoirs:
   - Animal reservoirs include white-tailed deer, dogs, and small rodents. Ruminants are also considered a reservoir for anaplasmosis.
   - Vectors in the United States:
     - *R. rickettsii*: Dermacentor variabilis (American dog tick), *Dermacentor andersoni* (Rocky Mountain wood tick), and *Rhipicephalus sanguineus* (brown dog tick).
     - *Rickettsia parkeri*: *Amblyomma maculatum* (Gulf Coast tick)
     - *Rickettsia akari*: *Liponyssoides sanguineus* (house mouse mites)
     - *Rickettsia species* 364D: Dermacentor occidentalis (Pacific Coast tick).
     - *E. chaffeensand E. ewingiiis*: *Amblyomma americanum* (Lone Star tick)
     - *A. phagocytophilum*: *Ixodes scapularis* (blacklegged tick) and *Ixodes pacificus* (western blacklegged tick).

D. Mode(s) of Transmission:
   Transmission occurs from the bite of an infected tick. For RMSF, transmission can also occur by the contamination of broken skin with the crushed tissue or feces of a tick and laboratory data suggest that the tick must remain attached for 4 - 6 hours before transmission occurs.

E. Incubation Period:
   - 7-14 days for human ehrlichiosis and anaplasmosis.
   - 2-21 days for spotted fever group rickettsial infections.

F. Period of Communicability:
   Not communicable person-to-person; ticks remains infective for life.
G. Susceptibility and Resistance:
   All persons are susceptible.

H. Treatment:
   Anaplasmosis, ehrlichiosis and Rocky Mountain spotted fever are treated with
doxycycline. Clinical suspicion of any of these diseases is sufficient to begin
treatment. Delay in treatment of rickettsial diseases may lead to severe illness or
death. Children are five times more likely than adults to die from RMSF. Doxycycline
is recommended by the American Academy of Pediatrics (AAP) and CDC for the
treatment of any suspected rickettsial diseases in patients of all ages. According to
the CDC, it is most effective when given within the first 5 days of illness.

NOTIFICATION TO PUBLIC HEALTH AUTHORITIES

Suspected cases of tickborne rickettsial disease (including anaplasmosis, ehrlichiosis,
and spotted fever rickettsiosis) shall be reported 24 hours, except if the reporting
period ends on a weekend or state-approved holiday, the report shall be made by
5:00 p.m. on the next business day after the 24-hour period:
1. Health care providers and hospitals: report to the local public health jurisdiction.
2. Local public health jurisdiction: report to KDHE-BEPI (see below).
3. Laboratories: report to KDHE-BEPI (see below).

Further responsibilities of state and local health departments to the CDC:
As a nationally notifiable condition, confirmed and probable cases require a ROUTINE
report to the Center of Disease Control and Prevention (CDC).
   1. ROUTINE reporting requires KDHE-BEPI to file an electronic report for within
      the next reporting cycle.
   2. Local public health jurisdiction will report information requested as soon as
      possible, ensuring that the electronic form is completed within 14 days of
      receiving a notification of a TBRD report.

INVESTIGATOR RESPONSIBILITIES
1) Report all TBRD cases to the KDHE-BEPI.
2) Contact medical provider to collect additional information and confirm
diagnosis using current case definition.
   • Initiate the investigation within 3 days of notification of a report.
   • Collect all information requested in Step 1 of case investigation.
   • Ensure that case/proxy is aware of the diagnosis.
3) Continue the case investigation for confirmed and probable cases to determine
   the risks of exposure and potential geographical location of exposure.
   • Complete the investigation within 14 days of the notification.
4) Record data, collected during the investigation, in the KS EpiTrax system
   under the data’s associated [tab] in the case morbidity report (CMR).
5) As appropriate, use the disease fact sheet to notify and educate.
STANDARD CASE INVESTIGATION AND CONTROL METHODS

Case Investigation

1) Contact the medical provider who ordered testing of the case and obtain the following information. (This includes medical records for hospitalized patients.)
   - Did the medical provider diagnose a TBRD?
     - Yes: Record the diagnosis date and continue the investigation.
     - No, not diagnosed based on negative IgM testing alone: Discuss with provider that IgM results alone should not be used for diagnosis and continue with the investigation if needed based on other findings.
     - No, not diagnosed based on other findings: Record the alternative diagnosis in the [Notes] of EpiTrax. No further investigation required. “Complete” and “Approve” the case as directed in Data Management.
   - Obtain information on any laboratory tests performed.
     - Complete blood cell counts (CBC) and differential results.
     - Liver enzyme testing results.
     - Any tickborne disease testing results that has not been reported.
   - Record onset date of first symptoms associated to this episode.
   - Symptoms: fever, rash, headache, myalgia, anemia, leukopenia, thrombocytopenia, elevated hepatic transaminases, eschar, or other symptoms.
   - Immunocompromised patient?
   - Complications: adult respiratory distress syndrome (ARDS), disseminated intravascular coagulopathy (DIC), meningitis/encephalitis, renal failure, other or none.
   - Collect patient’s demographics (address, birth date, gender, race/ethnicity, primary language, and phone number(s)).
   - Record treatment: type of antibiotic and number of days prescribed.
   - Record hospitalizations: location and duration of stay.
   - Record outcomes: survived or date of death.
   - Record pregnancy status for women.

2) Establish if the patient’s illness is clinically compatible to TBRD based on lab criteria and clinical symptoms.
   - If any of the following situations are present, no further investigation is necessary. Case will be closed as ‘Not a Case’ or ‘Suspect’ based on case definition.
     - The medical provider states it is not a case of TBRD and gives an alternative diagnosis
     - There was no fever (subjective or measured).
     - There was fever reported but no other TBRD symptoms were present (continue investigation if any symptoms are unknown).
   - Only probable or confirmed cases require further investigation.
3) If a continued investigation is needed and the patient charts do not provide information on all symptoms or on the following risk factors or travel, interview the case to determine risk factors and transmission.
   - Record patient’s occupation.
   - Thirty days prior to patient’s illness onset, was there a history of a tick bite.
     - Where was the patient when the tick bite occurred? (What county?)
   - Thirty days prior to patient’s illness onset, was there any exposure to wooded or brushy areas or exposure to animals that may have been in a wooded/brushy area?
     - Where were the wooded or brushy areas located that were associated to direct or indirect exposure during the 30 days prior to illness onset?
   - Was there travel to other Kansas counties? (If yes, City/County and dates)
   - Was there travel outside of Kansas?
     - Travel in the U.S.? (If yes, City/State and dates)
     - Travel internationally? (If yes, City/Country and dates)

4) Examining the epidemiological information, record under [Investigation] where the infection was most likely imported from. (Indigenous or out-of-county, state, or U.S.); also record the county, state, and country that was the most likely exposure.

**Contact Investigation**

Not usually required, these diseases cannot be transmitted from person-to-person, but an individual living in the same household, travel companions, co-workers, and anyone else who might be exposed to infected ticks is potentially at risk.

**Isolation, Work and Daycare Restrictions**

None.

**Case Management**

Not required.

**Contact Management**

1) Preventive treatment is not warranted.
2) Instruct those exposed to a tick to monitor themselves for symptoms. Treatment is necessary only if symptoms develop.
3) Those who exhibit any signs or symptoms compatible with tick-borne illness should be referred to their medical provider for evaluation.

**Environmental Measures**

**Veterinary tick control in domestic animals:**

1) Domestic animals may become infected with TBRD bacteria.
2) Domestic animals can carry infected ticks into areas where people live.
3) Veterinary tick-control products help to reduce tick presence on pets.

**Community-based integrated tick management strategies:**

1) May reduce the incidence of tick-borne infections, but limiting exposure to ticks
is the most effective method of prevention

2) Strategies to reduce vector tick densities through area-wide application of an acaricide (i.e., chemicals that kill ticks and mites) and control of tick habitats (e.g., leaf litter and brush) have been effective in small-scale trials.

3) New methods under development include applying acaricide to rodents and deer by using baited tubes, boxes and deer feeding stations in areas where these pathogens are endemic.

4) Biological control with fungi, parasitic nematodes, and parasitic wasps may play important roles in integrated tick control efforts.

Additional measures that can assist with determining risk include:

- Entomologic surveys: Inventory and mapping of tick populations sometimes with limited testing for TBRD. This can occur as part of special studies and through monitoring at deer and other animals.
- Testing of ticks: Kansas State University (KSU) Veterinary Diagnostic Laboratory does offer a fee for use service that tests ticks for RMSF.
  - All clinical decisions should be made based on the patient’s clinical signs and symptoms not tick testing results.
- Tick identification: Contact your local K-state extension office or refer to online Tick ID resources

Education

As opportunities allow, the following general messages should be distributed:

1) It is a good idea to take preventive measures against ticks year-round but be extra vigilant in warmer months (April-September).

2) The use of protective clothing, including light-colored garments, long pants tucked into socks, long-sleeved shirts, hats, as well as tick repellents, may reduce risk.

3) Outdoor activities in tick-infested areas present opportunities for exposure.

4) Keep yards clear of excessive leaves, brush, and tall grasses.

5) Walk in the center of trails to avoid contact with tall grasses and brush.

6) When camping, sleep in screened tents.

7) Hunters should be aware of tick infestations on mammals, especially deer, and check for ticks after handling carcasses.

8) Keep pets free of ticks.

9) Frequent tick checks increase the likelihood of finding a tick before it can transmit disease.

10) Remove attached ticks intact, do not leave embedded head parts. Use gentle, direct traction with tweezers or hemostat. Other methods, such as application of a hot match or petroleum products to the tick, are less reliable. Do not crush ticks as this may result in direct inoculation of TBDR bacteria.

Additional education materials are available at: www.cdc.gov/ticks/index.html
DATA MANAGEMENT AND REPORTING TO THE KDHE

A. Accept the case assigned to the LHD and record the date the LHD investigation was started on the [Administrative] tab.

B. Organize and collect data, using appropriate data collection tools including:
   - The Tick-Borne Rickettsial Report Form can be used to collect information.
   - Alternatively, investigators can collect and enter all required information directly into EpiTrax [Investigation], [Clinical], [Demographics] tabs.
   - During outbreak investigations, refer to guidance from a KDHE epidemiologist for appropriate collection tools.

C. Report data collected during the investigation via EpiTrax.
   - Verify that all data requested on the Tick-Borne Rickettsial Report Form has been recorded on an appropriate EpiTrax [tab], or that actions are completed for a case lost to follow-up as outlined below.
   - Some data that cannot be reported on an EpiTrax [tab] may need to be recorded in [Notes] or scanned and attached to the record.
   - Paper report forms do not need to be sent to KDHE after the information is recorded and/or attached in EpiTrax. The forms should be handled as directed by local administrative practices.

D. If a case is lost to follow-up, after the appropriate attempts to contact the case have been made:
   - Indicate ‘lost to follow-up’ on the [Investigation] tab with the number of attempts to contact the case recorded.
   - Record at least the information that was collected from the initial reporter.
   - Record a reason for ‘lost to follow-up’ in [Notes].

E. Once the investigation is completed, the LHD investigator will record the date the investigation was completed on the [Administrative] tab and click the “Complete” button. This will trigger an alert to the LHD Administrator so they can review the case before sending to the state.
   - The LHD Administrator will then “Approve” or “Reject” the CMR.
   - Once a case is “Approved” by the LHD Administrator, BEPHI staff will review and close the case after ensuring it is complete and that the case is assigned to the correct event, based on the reported symptoms reported. (Review the EpiTrax User Guide, Case Routing for further guidance.)
ADDITIONAL INFORMATION / REFERENCES


C. Case Definitions: CDC Division of Public Health Surveillance and Informatics, Available at: wwwn.cdc.gov/nndss/

D. Kansas Regulations/Statutes Related to Infectious Disease: www.kdheks.gov/epi/regulations.htm


F. Additional Information (CDC): www.cdc.gov/ticks/index.html
Heartland and Bourbon Virus Testing Update

July 20, 2018

Background

Heartland virus was first discovered as a cause of human illness in 2009 in Missouri. More than 35 cases of Heartland virus disease have been reported from states in the Midwestern and southern United States to date. Most people with the disease became sick during May through September.

Bourbon virus was recently discovered in Bourbon County, Kansas. Only a few cases of Bourbon virus disease have been identified in the U.S., and the geographic distribution appears to be similar to that of Heartland virus. Although it is not yet known how people become infected with Bourbon virus, most patients reported exposure to ticks before becoming ill and the virus has been identified in Lone Star ticks.

Since the discovery of these viruses, Kansas has identified one Heartland virus case and one Bourbon virus case.

Symptoms for both diseases have included fever, fatigue, anorexia, nausea, and diarrhea. Patients with Bourbon virus disease might also present with a diffuse, maculopapular rash. Both viruses have been found to cause leukopenia, thrombocytopenia, and elevated liver transaminases.

Update on status of Heartland and Bourbon virus testing

For several years, CDC has been working with state health departments under IRB-approved protocols to identify additional cases of Heartland and Bourbon virus disease and validate diagnostic tests for these viruses. Enrollment into these protocols has been concluded and CDC Arboviral Diseases Branch will now offer routine diagnostic testing for Heartland and Bourbon viruses.

Testing Criteria

Testing for Heartland or Bourbon virus should be considered for patients with an acute febrile illness within the past three months AND at least one epidemiologic criterion AND at least one clinical criterion.

Epidemiologic criteria

1) Known tick bite, finding a tick on body, or potential exposure to ticks through outdoor activities in the three weeks prior to illness onset during spring through fall (e.g., April-October); OR
2) Resides in or recently traveled to an area with previous evidence of Heartland or Bourbon virus (primarily eastern/central Kansas or Missouri)

Clinical criteria

1) Leukopenia (white blood cells <4,500 cells/µL) or thrombocytopenia (platelets <150,000 cells/mL) not explained by another known condition; OR
2) Suspected tickborne disease (e.g., ehrlichiosis, Rocky Mountain spotted fever) with no clinical response to appropriate treatment (e.g., doxycycline)

Samples collected >3 months after symptom onset will not be tested at this time based on limitations of current understanding of antibody response.
Testing for evidence of Heartland and Bourbon virus disease

As of July 2018, the following tests for Heartland and Bourbon virus are available at CDC:

<table>
<thead>
<tr>
<th>Test</th>
<th>Heartland virus</th>
<th>Bourbon virus</th>
</tr>
</thead>
<tbody>
<tr>
<td>RT-PCR</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>IgM MIA</td>
<td>Yes</td>
<td>Not available</td>
</tr>
<tr>
<td>IgG MIA</td>
<td>Yes</td>
<td>Not available</td>
</tr>
<tr>
<td>PRNT</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

Abbreviations: IgM – immunoglobulin M; IgG – immunoglobulin G; MIA – microsphere-based immunoassay; RT-PCR – reverse transcriptase-polymerase chain reaction; PRNT – plaque reduction neutralization test

For specimens collected <7 days after onset of symptoms, serum and/or whole blood should be submitted for Heartland and Bourbon virus RT-PCR and antibody testing.

For specimens collected ≥7 days after onset of symptoms, serum specimens should be submitted for antibody testing. If the patient is immunocompromised, RT-PCR also may be performed on serum collected >7 days after onset.

Because there is no specific IgM antibody test yet available for Bourbon virus, acute and convalescent samples will be needed to make the diagnosis of an acute Bourbon virus infection using serologic assays.

Submitting specimens to CDC for testing

To submit samples for Heartland and Bourbon virus testing at the CDC Arboviral Disease Branch, please contact the KDHE Epidemiology Hotline at 877-427-7317 for approval.

Additional information
